• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Block Listing Return and Total Voting Rights

by admin | Jul 1, 2024 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Change of Nominated Advisor

by admin | Jun 21, 2024 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell Signs Agreement with Major International Biotechnology Company to Evaluate an Antibody in the Glymab® Portfolio

by admin | Jun 12, 2024 | GlyMab, Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell receives MHRA approval to expand ModiFY trial

by admin | May 30, 2024 | Latest News, Modi-1, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell to present at the 2024 ASCO Annual Meeting

by admin | May 24, 2024 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell to present at the Sachs 10th Annual Oncology Innovation Forum

by admin | May 21, 2024 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
« Older Entries
Next Entries »

Recent Posts

  • Active Immunotherapy: Ready For Prime Time
  • Strategic transactions to unlock longer-term value
  • Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
  • iSCIB1+ pivotal trial plans advancing
  • AACR (American Association for Cancer Research) Annual Meeting, April 2026, San Diego, California

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy